This small-cap pharmaceutical company gets final approval from USFDA for famotidine tablets
Shares of the company have gained more than 27 per cent in the last six months.
On Friday, the shares of Marksans Pharma closed at Rs 68.75, up by 1.57 per cent from its previous closing of Rs 67.69 on the BSE.
Marksans Pharma has received final FDA approval for its Abbreviated New Drug Application (ANDA) for Famotidine Tablets USP, 10 mg and 20 mg for over-the-counter (OTC) use. The product is bioequivalent to Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer Inc. with over $200 million in sales in the US market.
Marksans' OTC Famotidine Tablets USP, 10 mg and 20 mg, are acid reducers which used to treat conditions where reduction of stomach acid is needed, such as acid indigestion, occasional heartburn, or sour stomach from eating or drinking specific foods or beverages.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is the distribution of pharmaceutical products.
On 10th March, the stock opened at Rs 66.11 and has touched a high and low of Rs 69 and Rs 66, respectively.
The BSE group 'A' stock of face value of Rs 1 has touched a 52-week high and low of Rs 72.25 and Rs 38.70, respectively.
The company has a ROCE of 23.9 per cent and an ROE of 18.5 per cent, with a market capitalisation of Rs 3,115.50 crore.
The promoters holding in the company stood at 49.00%, while Institutions and Non-Institutions held 5.20% and 45.80 per cent, respectively.